SCHEMBL219109

SCHEMBL219109

O=Cc1ccc(O)c(F)c1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.64
PTGS2 P35354 1/20 0.64
RAB9A P51151 1/20 0.64
ALDH1A1 P00352 5/20 0.52
ALDH5A1 P51649 3/20 0.52
ABAT P80404 3/20 0.52
TRIM24 O15164 1/20 0.52
HPGD P15428 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
TRIM33 Q9UPN9 1/20 0.52
SNCA P37840 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.47
AOX1 Q06278 1/20 0.47
KDM1A O60341 2/20 0.46
SIRT1 Q96EB6 1/20 0.44
ESR1 P03372 2/20 0.44
ESR2 Q92731 2/20 0.44
LMNA P02545 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29465560 1.00 KDM4E (0.64) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL4367977 0.82 KDM4E (0.48) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL1922774 0.82 KDM4E (0.64) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL29887017 0.79 KDM4E (0.50) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL6619511 0.79 HSD17B1 (0.59) KDM4EPTGS2RAB9ATRIM24TRIM33
SCHEMBL29389102 0.78 ALDH1A1 (0.52) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL48607 0.78 ALDH1A1 (0.52) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
Protocatechualdehyde SCHEMBL36350 0.78 KDM4E (1.00) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
Protocatechualdehyde SCHEMBL9512877 0.78 KDM4E (1.00) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
Protocatechualdehyde SCHEMBL29349539 0.78 KDM4E (1.00) KDM4EPTGS2RAB9AALDH1A1ALDH5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 936 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120081885-A Substituted phenyl glycoside compound and preparation method and application thereof 浙江大学 2025-06-03 CN claimed
CN-119439624-A Imine-based high-performance ultraviolet shielding photoresist and preparation method thereof 中国工程物理研究院激光聚变研究中心 2025-02-14 CN claimed
CN-117658887-A Fluorescent probe for detecting heavy water content in water 遵义医科大学 2024-03-08 CN claimed
CN-117623931-A Preparation method of safe and environment-friendly mono-nitro aromatic hydrocarbon 清源创新实验室 2024-03-01 CN claimed
CN-115650930-B Diaryl ethylene fluorescent molecular material, diaryl ethylene hydrogel material, and preparation and application thereof 浙江大学杭州国际科创中心 2023-11-03 CN claimed
CN-115650930-A Diarylethene fluorescent molecular material, diarylethene hydrogel material, preparation and application thereof 浙江大学杭州国际科创中心 2023-01-31 CN claimed
CN-114634501-A 3, 5-diaryl-thiazolidone-azo chain-indolone derivative and preparation method and application thereof 复旦大学 2022-06-17 CN claimed
CN-103304408-A Preparation method of roflumilast intermediate 3-cyclopropyl methoxy-4-difluoromethoxybenzoic acid WEIHAI DISU PHARMACEUTICAL CO LTD 2013-09-18 CN claimed
EP-1778011-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OF UBIQUITIN CONJUGATING DISORDERS Hygeia Biological Systems (US) 2007-05-02 EP claimed
WO-2006020681-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OF UBIQUITIN CONJUGATING DISORDERS HYGEIA BIOLOGICAL SYSTEMS (US) 2006-02-23 WO claimed
US-20060035890-A1 Compounds and methods for the treatment of ubiquitin conjugating disorders AMIT BANERJEE 2006-02-16 US claimed
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors AXYS PHARMACEUTICALS, INC. 2004-01-22 US claimed
US-6492362-B1 Compounds and compositions as cathepsin S inhibitors AXYS PHARMACEUTICALS, INC. 2002-12-10 US claimed
WO-2001019808-A1 CHEMICAL COMPOUNDS AND COMPOSITIONS AND THEIR USE AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-03-22 WO claimed
US-12630509-B2 Heterocyclic NMDA antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2026-05-19 US disclosed
CN-122050597-A End-to-end drug design method and device based on multi-agent cooperation 深圳大学 2026-05-15 CN disclosed
EP-4055016-B1 GPR52 MODULATOR COMPOUNDS NXERA PHARMA UK LTD (GB) 2026-04-29 EP disclosed
EP-0197677-A2 Halogen-containing, optically active liquid crystal compound and liquid crystal composition containing same Chisso Corporation (JP) 1986-10-15 EP disclosed
US-3972945-A Process for the selective synthesis of salicylaldehydes THE GARRETT CORPORATION (US) 1976-08-03 US disclosed
US-3972945-A Process for the selective synthesis of salicylaldehydes THE GARRETT CORPORATION (US) 1976-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630509-B2 Heterocyclic NMDA antagonists GRIN1, GRIN3A, GRIN2B KDM4E 575/4885PTGS2 1981/4885RAB9A 1701/4885
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors CTSS, CTSB, CTSE KDM4E 4465/4885PTGS2 1829/4885RAB9A 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.